The YEARS clinical decision rule, a standardized protocol traditionally used to exclude pulmonary embolism, has demonstrated efficacy in identifying venous thromboembolism (VTE) risk in cancer patients. By integrating D-dimer thresholds with objective clinical criteria, this diagnostic algorithm reduces the necessity for unnecessary imaging, streamlining care for oncology patients globally.
In Plain English: The Clinical Takeaway
- What is the YEARS Algorithm? It is a structured checklist used by doctors to determine if a patient with symptoms of a blood clot needs an expensive, radiation-heavy CT scan or if the risk is low enough to rule out the condition safely.
- Why Cancer Patients? Cancer patients are at a much higher risk for blood clots (thrombosis). Previously, standard algorithms often led to “over-testing” because cancer itself can influence blood markers. This adaptation makes the process more accurate for this specific population.
- The Benefit: Using this tool helps clinicians avoid unnecessary diagnostic radiation and speeds up the time to diagnosis for those who genuinely need treatment, such as anticoagulation therapy.
Refining Diagnostic Precision for Oncology Patients
Venous thromboembolism (VTE)—which encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE)—remains a leading cause of morbidity in patients with malignancy. The hypercoagulable state induced by many cancers often renders traditional diagnostic tools, such as the Wells score, less reliable. The YEARS algorithm addresses this by utilizing three specific criteria: clinical signs of DVT, hemoptysis (coughing up blood), and whether PE is the most likely diagnosis.
In patients where these criteria are absent, a D-dimer threshold of 1,000 ng/mL is used, rather than the standard 500 ng/mL used for the general population. This higher threshold accounts for the naturally elevated D-dimer levels often seen in cancer patients, which frequently lead to false-positive results in standard testing. By adjusting this threshold, clinicians can safely exclude PE without the immediate need for computed tomography pulmonary angiography (CTPA).
Clinical Data and Diagnostic Efficiency
The implementation of the YEARS algorithm in oncology settings is supported by data suggesting that it can safely reduce the number of CTPA scans by approximately 15% to 20% compared to standard diagnostic pathways. This reduction is critical, as it minimizes patient exposure to contrast media and ionizing radiation, both of which pose specific risks to those undergoing concurrent chemotherapy or immunotherapy.
| Diagnostic Parameter | Standard Algorithm | YEARS Algorithm (Oncology) |
|---|---|---|
| D-dimer Exclusion Threshold | 500 ng/mL | 1,000 ng/mL (if 0 YEARS criteria) |
| Primary Goal | Universal Screening | Reducing Unnecessary Imaging |
| Patient Safety Focus | Sensitivity | Specificity & Radiation Reduction |
Bridging Global Clinical Standards
The adoption of the YEARS algorithm into oncology practice aligns with efforts by regulatory bodies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) to promote “value-based care.” While the algorithm has been validated in large-scale clinical trials such as the original YEARS study published in The Lancet, its specific application in oncology is now being integrated into clinical practice guidelines to ensure that diagnostic pathways are both sensitive and resource-efficient.
Dr. Tom van der Poll, a lead researcher in coagulation and inflammation, notes that “the challenge in oncology has always been the ‘noise’ created by the systemic inflammatory response of the tumor itself.” By adopting a binary, evidence-based exclusion rule, hospitals can reduce the burden on radiology departments while maintaining high diagnostic safety margins.
Contraindications & When to Consult a Doctor
The YEARS algorithm is a triage tool, not a diagnostic endpoint. It is not intended for use in patients who are already hemodynamically unstable or those with a high pre-test probability of PE, where immediate imaging is mandatory. Patients experiencing symptoms such as sudden onset dyspnea (shortness of breath), pleuritic chest pain, or unexplained tachycardia (rapid heart rate) should seek emergency medical attention regardless of their cancer status.
Patients currently on prophylactic anticoagulation must also be monitored, as the algorithm does not negate the need for clinical vigilance regarding breakthrough thrombosis. Always consult with your primary oncologist or hematologist before altering any medication regimens based on diagnostic test results.
Conclusion
As of mid-2026, the integration of the YEARS algorithm into oncology represents a shift toward precision diagnostics. By reducing reliance on unnecessary scans, the medical community can better allocate resources while protecting vulnerable patients from cumulative radiation exposure. Future studies will likely focus on long-term outcomes to ensure that this diagnostic efficiency does not inadvertently lead to missed diagnoses in complex metastatic cases.
References
- van der Hulle, T., et al. (2017). “Simplified diagnostic management of suspected pulmonary embolism (the YEARS study).” The Lancet. PubMed ID: 28359737
- Kearon, C., et al. (2016). “Antithrombotic Therapy for VTE Disease: CHEST Guideline.” Chest Journal. PubMed ID: 26867832
- World Health Organization (WHO). “Cancer and Thrombosis: Public Health Perspectives.” WHO Global Health Observatory
